• Syed Saleem Abbas Jafri
  • Muhammad Saleem Akhter
  • Mumtaz Ahmad
  • Sajjad Hussain


Background: The primary objective of this study was to determine the efficacy, safety and compliance of terazosin, aselective long-acting alpha 1-blocker, for the treatment of symptomatic BPH. Methods: A total of 150 patients rangingin age between 45 and 81 years with symptomatic BPH were included. They were randomly assigned to receiveterazosin (n =74) or placebo (n = 76) for 12 weeks. Results: Terazosin significantly improved urinary symptoms versusplacebo, assessed by using the 1-PSS (-30vs. -17%, P=0.007). Maximum flow rate increased significantly withterazosin (2.3 ml/s i.e. ± 28%) compared with placebo (1.1 ml/s i.e. ±13%, P=0.006). Residual urine was alsosignificantly reduced with terazosin. Overall, terazosin was as well tolerated as placebo. Seven patients werewithdrawn from the study for adverse events with terazosin (9.45%) and eight patients (10.52%) with placebo. Theincidence of vasodilatation-related events like postural symptoms, dizziness, headache with terazosin was similar(8.11%) to that of placebo (7.90%). The reduction in supine blood pressure was minor (< 5mm Hg), both innormotensive and hypertensive patients. Conclusion: This study demonstrates the efficacy, safety and compliance ofterazosin for the treatment of BPH.


Berry, S.J., Coffery, D. S., Walsh, P.C. and Ewing,

L; The development of human benign prostatic

hypertrophy with age. J. Urol., 1984;132:474-

Rutkow. I.M.: Urological operations in the United

States, 1979-1984. J. Urol., 1986; 13 5:1206

Turner-war wick, R., Whiteaide, C.G., Arnold,

E.T.et al.: A Urodynamic view of prostatic

obstruction and results of prostatectomy. Br. J.

Urol., 1973;451:631.

Ball, A.J.; Feneley, R.C. L and Abrams, P.H.: The

natural history of untreated “prostatism”.


Cockett, A. T.K., Aso, Y., Denis, L.et.al.:

Recommendations of the International Consensus

Committee Concerning: 4.BPH treatment

recommendations. Im Cocktt, A.T.K. et. al.

Editors. The 2nd International Consultations on

Benigin Prostatic Hyperplasia(BPH), Paris,


Caine, M: Alpha-adrenergic blockers for the

treatment of benign prostatic hyperplasia. Urol.

Clin.N.Amer.,1990;17: 641-649.

Lepor, H., Shapiro, E., Gup, D.I. et. al.:

Laboratory assessment of terazosin and alpha 1

blockade in prostatic hyperplasia. Urology,


Lepor, H.: Pharmacologic management of benign

prostatic hyperplasia. In:1992: Urology Annual.

Edited by Rous, S.N., Norwalk, 1991,PP. 1 -19.

Caine, M., Pfau, A. and Perlbery.S.: The use of

alpha- adrenergic blockers in benign prostatic

obstruction. Br.J.Urol.,1976;48:255.

Hedlund, H. and Andersen, K.E., Ek. A.: Effects

of prazosin in patients with benign. prostatic

obstruction. J.Urol.,1983; 130:275.

Lacorow, J.W. and Dunn, M.: Indoramin: An

effective new drug in the management of bladder

outflow obstruction.Br.J.Urol.,1987; 60:526.

Ramsay, J.W. A., Scott, G. l. and Whitfield, H. N.:

A double-blind controlled trial of a new alpha 1

blocking drug in the treatment of bladder outflow

obstruction. Br. J. Urol., 1985;57:657.

Caine, M., Mazouz, B. and Rossini, B.M.: The

effect of nicergoline on the lower urinary tract

muscle. Urol.Res., 1984; 12:287.

Anderson, K. E., Hedlund, H., Larsson, B et. al.:

Ketanserine interaction with urethral alphaadrenoreceptors. J. Urol., 1987. 37:534.

JAMC, Vol. 12, No. 2, 2000

Lepor. H., Baumann, M. and Shapiro, E.: The

alpha-adrenergic binding properties of terazosin

in the human prostate adenoma and caine brain.


Dunzendrofer, U.: Clinical experience.

Symptomatic management of BPH with terazosin

therapy. Urology. 1988;32 (Suppl.): 27.

Lipsitz, L. A.: orthostatic hyperplasia in the

elderly. New Engl.J.med.,1989;321:952.

Chappie, C.R., Carter, P., Christmas, T. J. et. al.:

A three-month double blind study of doxazosin as

treatment of benign prostatic bladder outlet


Lepor, H., Meretyk, S. and Knapp-.Maloney. G:

The safety, efficacy and compliance of terazosin

thrapy for benign prostatic hyperplasia. J. Urol.,

; 147:1554.

Lepor, H., Auerbach, S., Puras-Baez, A. et. al.: A

randomized, placebo controlled multicenter study

of the efficacy and safety of terazosin in the

treatment of benign prostatic hyperplasia. J.

Urol., 1992; 148:1467-1474.

Most read articles by the same author(s)